1. Anti-infection
  2. HCV

ABT-333 (Synonyms: Dasabuvir)

Cat. No.: HY-13998 Purity: 97.93%
Data Sheet SDS Handling Instructions

ABT-333 is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM.

For research use only. We do not sell to patients.
ABT-333 Chemical Structure

ABT-333 Chemical Structure

CAS No. : 1132935-63-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $121 In-stock
5 mg $110 In-stock
10 mg $180 In-stock
50 mg $400 In-stock
100 mg $650 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

ABT-333 is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM.

IC50 & Target

IC50: 2.2-10.7 nM (NS5B polymerase)[1]

In Vitro

ABT-333 (Dasabuvir) is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. ABT-333 (Dasabuvir) inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s between 2.2 and 10.7 nM. ABT-333 inhibits replication of HCV subgenomic replicons in cell culture assays, with EC50 values of 7.7 and 1.8 nM against genotype 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC50s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively[1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02052349 AbbVie Relative Bioavailability November 2013 Phase 1
NCT01704755 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis October 2012 Phase 3
NCT02534870 AbbVie Healthy Volunteer September 2015 Phase 1
NCT00895102 Abbott HCV Infection April 2009 Phase 1
NCT01674725 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection August 2012 Phase 3
NCT00909636 Abbott HCV Infection May 2009 Phase 1
NCT00726882 AbbVie (prior sponsor, Abbott)|AbbVie HCV Infection August 2008 Phase 2
NCT01911845 AbbVie Chronic Hepatitis C Infection|Chronic Hepatitis C April 2013 Phase 2
NCT00851890 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Virus Infection March 2009 Phase 2
NCT00919490 Abbott|Abbott Japan Co.,Ltd HCV Infections June 2009 Phase 1
NCT01306617 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus February 2011 Phase 2
NCT02167945 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 June 12, 2014 Phase 3
NCT02219490 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 October 30, 2014 Phase 3
NCT02517515 AbbVie Chronic Hepatitis C Virus July 16, 2015 Phase 3
NCT01767116 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection December 2012 Phase 3
NCT01074008 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 March 2010 Phase 2
NCT01833533 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT02517528 AbbVie Chronic Hepatitis C Virus July 2015 Phase 3
NCT01716585 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT01715415 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT00696904 Abbott HCV Infection June 2008 Phase 1
NCT00768690 Abbott HCV Infection October 2008 Phase 1
NCT01939197 AbbVie Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics August 2013 Phase 3
NCT01464827 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 October 2011 Phase 2
NCT01854528 AbbVie Chronic Hepatitis C Infection June 2013 Phase 3
NCT01563536 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection February 2012 Phase 2
NCT01854697 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT01782495 AbbVie Chronic Hepatitis C Infection February 25, 2013 Phase 2
NCT01773070 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C June 2013 Phase 3
NCT01995071 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis November 2013 Phase 2
NCT02734173 Ottawa Hospital Research Institute|AbbVie Hepatitis C July 2015 Phase 4
NCT02052349 AbbVie Relative Bioavailability November 2013 Phase 1
NCT01704755 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis October 2012 Phase 3
NCT02534870 AbbVie Healthy Volunteer September 2015 Phase 1
NCT00895102 Abbott HCV Infection April 2009 Phase 1
NCT01674725 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection August 2012 Phase 3
NCT00909636 Abbott HCV Infection May 2009 Phase 1
NCT00726882 AbbVie (prior sponsor, Abbott)|AbbVie HCV Infection August 2008 Phase 2
NCT01911845 AbbVie Chronic Hepatitis C Infection|Chronic Hepatitis C April 2013 Phase 2
NCT00851890 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Virus Infection March 2009 Phase 2
NCT00919490 Abbott|Abbott Japan Co.,Ltd HCV Infections June 2009 Phase 1
NCT01306617 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus February 2011 Phase 2
NCT02167945 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 June 12, 2014 Phase 3
NCT02219490 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 October 30, 2014 Phase 3
NCT02517515 AbbVie Chronic Hepatitis C Virus July 16, 2015 Phase 3
NCT01767116 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection December 2012 Phase 3
NCT01074008 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 March 2010 Phase 2
NCT01833533 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT02517528 AbbVie Chronic Hepatitis C Virus July 2015 Phase 3
NCT01716585 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT01715415 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT00696904 Abbott HCV Infection June 2008 Phase 1
NCT00768690 Abbott HCV Infection October 2008 Phase 1
NCT01939197 AbbVie Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics August 2013 Phase 3
NCT01464827 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 October 2011 Phase 2
NCT01854528 AbbVie Chronic Hepatitis C Infection June 2013 Phase 3
NCT01563536 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection February 2012 Phase 2
NCT01854697 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT01782495 AbbVie Chronic Hepatitis C Infection February 25, 2013 Phase 2
NCT01773070 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C June 2013 Phase 3
NCT01995071 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis November 2013 Phase 2
NCT02734173 Ottawa Hospital Research Institute|AbbVie Hepatitis C July 2015 Phase 4
NCT02582632 AbbVie Hepatitis C Infection|Hepatitis C Virus November 2015 Phase 3
NCT02219503 AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis September 2014 Phase 3
NCT03122132 Hepa C Hepatitis C Infection February 20, 2017
NCT02609659 AbbVie Chronic Hepatitis C Infection October 2015 Phase 3
NCT02399345 AbbVie Chronic Hepatitis C Virus (HCV Infection Genotype 1) March 2015 Phase 3
NCT02476617 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 3
NCT02493855 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 2
NCT02504099 AbbVie Chronic Hepatitis C Infection July 2015 Phase 3
NCT02219477 AbbVie Chronic Hepatitis C|Decompensated Cirrhosis|Hepatitis C Virus November 24, 2014 Phase 3
NCT02356562 AbbVie Chronic Hepatitis C Infection February 3, 2015 Phase 2
NCT02207088 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease September 2014 Phase 3
NCT02487199 AbbVie HCV|Genotype 1a|Genotype 4|Chronic Kidney Disease|Hepatitis C|pegIFN|IFN September 2015 Phase 3
NCT02216422 AbbVie Chronic Hepatitis C Virus (HCV) Infection September 2014 Phase 3
NCT02442284 AbbVie Chronic Hepatitis C|Cirrhosis|Hepatitis C Virus May 2015 Phase 3
NCT02442271 AbbVie Chronic Hepatitis C Infection April 2015 Phase 3
NCT02950870 University of Modena and Reggio Emilia Chronic Hepatitis, C Virus December 2016 Phase 4
NCT02634008 Kirby Institute|AbbVie Hepatitis C, Acute June 2016 Phase 3
NCT02461745 Kaiser Permanente|AbbVie Hepatitis C, Chronic June 2015 Phase 4
NCT02486406 AbbVie Chronic Hepatitis C Infection October 28, 2015 Phase 3
NCT02786537 University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme Corp.|AbbVie Chronic Hepatitis C June 2016 Phase 4
NCT02194998 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections August 2015 Phase 2
NCT02555943 Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University Chronic Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation February 2015 Phase 2|Phase 3
NCT02758509 Parc de Salut Mar Chronic Hepatitis C|Cirrhosis January 1, 2010
NCT02460133 Lisa Barrett|PEI Provincial Correction Centre|Nova Scotia Health Authority Hepatitis C Virus July 2015 Phase 4
NCT02333292 Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias|Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell Chronic Hepatitis C Infection December 2014
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.0261 mL 10.1303 mL 20.2606 mL
5 mM 0.4052 mL 2.0261 mL 4.0521 mL
10 mM 0.2026 mL 1.0130 mL 2.0261 mL
Kinase Assay
[1]

The recombinant HCV polymerases used in this study contain the first 570 amino acids of the 591-amino acid native protein sequence, with a six-histidine tag at the N terminus to facilitate purification by affinity chromatography. Briefly, ABT-333 (Dasabuvir) is incubated with 5 to 50 nM polymerase for 15 min at room temperature, follow by the addition of nucleoside triphosphates (NTPs) and [3H]UTP for 3 h at 30°C. After termination of the reaction, the precipitated RNA is captured by filtration through a GF/B filter. The amount of incorporated [3H]UTP is measured by scintillation counting with a Wallac 1450 MicroBeta counter. The percent inhibition is calculated from the initial rates of inhibited reactions relative to that of the uninhibited control reaction. The mean 50% inhibitory concentration (IC50) and the standard error of the mean (SEM) are calculated via nonlinear regression[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

493.57

Formula

C₂₆H₂₇N₃O₅S

CAS No.

1132935-63-7

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 46 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 97.93%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ABT-333
Cat. No.:
HY-13998
Quantity: